Packman K - Search Results

1

Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.

Roy S, Packman K, Jeffrey R, Tenniswood M. Roy S, et al. Among authors: packman k. Cell Death Differ. 2005 May;12(5):482-91. doi: 10.1038/sj.cdd.4401581. Cell Death Differ. 2005. PMID: 15746940

2

Antiandrogen-induced cell death in LNCaP human prostate cancer cells.

Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M. Lee EC, et al. Among authors: packman k. Cell Death Differ. 2003 Jul;10(7):761-71. doi: 10.1038/sj.cdd.4401228. Cell Death Differ. 2003. PMID: 12815459

3

Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.

Zhan P, Lee EC, Packman K, Tenniswood M. Zhan P, et al. Among authors: packman k. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):101-11. doi: 10.1016/s0960-0760(02)00275-3. J Steroid Biochem Mol Biol. 2002. PMID: 12650706

4

Vitamin D(3) receptor ablation alters mammary gland morphogenesis.

Zinser G, Packman K, Welsh J. Zinser G, et al. Among authors: packman k. Development. 2002 Jul;129(13):3067-76. Development. 2002. PMID: 12070083

5

Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion.

Flanagan L, Packman K, Juba B, O'Neill S, Tenniswood M, Welsh J. Flanagan L, et al. Among authors: packman k. J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):181-92. doi: 10.1016/s0960-0760(03)00028-1. J Steroid Biochem Mol Biol. 2003. PMID: 12711002

6

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Tovar C, et al. Among authors: packman k. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. doi: 10.1073/pnas.0507493103. Epub 2006 Jan 27. Proc Natl Acad Sci U S A. 2006. PMID: 16443686 Free PMC article.

7

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.

Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC, Vassilev LT. Tovar C, et al. Among authors: packman k. Mol Cancer. 2011 May 3;10:49. doi: 10.1186/1476-4598-10-49. Mol Cancer. 2011. PMID: 21539745 Free PMC article.

8

Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.

Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C, Dugan U, Heimbrook D, Packman K. Higgins B, et al. Among authors: packman k. Anticancer Res. 2007 Jul-Aug;27(4B):2279-87. Anticancer Res. 2007. PMID: 17695515

9

In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.

DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Chen Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, Kolinsky K, Felix B, Hussain S, Heimbrook D. DePinto W, et al. Among authors: packman k. Mol Cancer Ther. 2006 Nov;5(11):2644-58. doi: 10.1158/1535-7163.MCT-06-0355. Mol Cancer Ther. 2006. PMID: 17121911

10

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G. Su F, et al. Among authors: packman k. Cancer Res. 2012 Feb 15;72(4):969-78. doi: 10.1158/0008-5472.CAN-11-1875. Epub 2011 Dec 28. Cancer Res. 2012. PMID: 22205714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results